🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,061 results for “Bio” Clear

  1. Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    The George Institute

    Patients with a histological diagnosis of p53abn HREC, treated with curative intent, after surgery (hysterectomy and bilateral salpingooophorectomy, with or without lymphadenectomy or sentinel node biopsy), without signs of residual disease or distant metastases

    phase 3 small molecule active

    1 trial

  2. MAT2203

    Matinas BioPharma Holdings

    Cryptococcal Meningitis

    phase 3 small molecule active

    2 trials

  3. MCV-ACYW135 Vaccine Group

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Meningitis

    phase 3 mab completed

    1 trial

  4. MESNA, MESNA, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Teva 25 mg/ml concentraat voor oplossing voor injectie of infusie, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan 1000 mg milteliai injekciniam tirpalui, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cycloph

    Iovance Biotherapeutics B.V.

    Melanoma

    phase 3 small molecule active

    1 trial

  5. MORE

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use

    phase 3 other active

    1 trial

  6. MORE and MI and NRT

    BRIGHT MINDS BIOSCIENCES INC.

    Polysubstance Abuse

    phase 3 other active

    1 trial

  7. Marijuana Check-Ins

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 3 other completed

    1 trial

  8. Matches test film-coated tablets, Wakix 4.5 mg film-coated tablets, Wakix 18 mg film-coated tablets

    Bioprojet Pharma

    Narcolepsy

    phase 3 small molecule active

    1 trial

  9. Matching Placebo for Piclidenoson, Piclidenoson

    Can-Fite BioPharma

    Plaque psoriasis

    phase 3 small molecule active

    1 trial

  10. Matching Placebo for TAK-279 Dose B, ZASOCITINIB, ZASOCITINIB, Matching Placebo for TAK-279 Dose A

    Takeda

    Active Psoriatic Arthritis Stratified by Prior Biologic Use

    phase 3 small molecule active

    1 trial

  11. Methadone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 3 small molecule terminated

    2 trials

  12. Methadone (100% dose)

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 3 small molecule active

    1 trial

  13. Methadone Treatment-As-Usual

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use

    phase 3 small molecule active

    1 trial

  14. Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Placebo of methylprednisolone (glucose 5%), placebo of prednisone, PREDNISONE ARROW 20 mg, comprimé sécable

    Pari Pharma GmbH

    Patients presenting with acute myocarditis proven by cardiac magnetic resonance imaging (CMRi) or by histological evidence on endomyocardial biopsy (EMB)

    phase 3 small molecule active

    1 trial

  15. Motivational interviewing

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 3 other completed

    1 trial

  16. Moxifloxacin

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis, Pulmonary, Drug Sensitive

    phase 3 small molecule completed

    1 trial

  17. Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Tuberculosis

    phase 3 small molecule completed

    1 trial

  18. N-Acetyl-L-Leucine, granules for suspension

    Intrabio Ireland Limited

    CACNA1A Disorders

    phase 3 small molecule active

    1 trial

  19. N-Acetylcysteine

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 3 small molecule completed

    2 trials

  20. N-acetylgalactosamine 4-sulfatase

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis VI

    phase 3 small molecule completed

    3 trials

  21. NBI-1065845

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  22. NBI-1065845

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    5 trials

  23. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  24. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources